n the midst of a worsening crisis over opioid use and prescribing, you might think a company would take every precaution to ensure its medicine is marketed carefully to physicians.

But one small drug maker failed to do so — in a big way.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.